

Press Release

24 September 2024 19:45:00 CEST

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)

Below is a summary of the resolution passed. Complete resolution can be found on the company's website. The resolution was passed with the required majority.

Changes to the Board of directors

At the Extraordinary General Meeting of 2cureX AB (publ) today, 24 September 2024, it was decided to elect Nathaniel Hutley and Dan Honeywell as new board members.

This election is part of a strategic initiative as 2cureX refines its strategy to facilitate the implementation of IndiTreat® testing across individual hospitals. Such a move towards decentralization necessitates an enhancement of the company's commercial and partnering expertise. Nathaniel Hutley and Dan Honeywell will be strong additions to the Board of Directors with international expertise in building global companies focussing on direct to customer business models.

The new Board members are described in detail at the 2cureX website (www.2curex.com).

The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Grith Hagel, Ole Thastrup, Nathaniel Hutley and Dan Honeywell.

For more information about 2cureX:

Ole Thastrup, CEO
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB

Attachments

[BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB \(PUBL\)](#)